At a glance
ClinicalIndex Comparison RecordN/ACompleted· 178 enrolled
Drug / intervention
Remicade (Infliximab)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Remicade Therapy in Psoriatic Arthritis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions
In Brief
An observational study evaluating Remicade (Infliximab) for Arthritis, Psoriatic. Completed, enrolled 178 participants.
Detailed Summary
This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Psoriatic
Countries--
CollaboratorsCentocor, Inc.
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2004
First PostedJul 2008
Primary CompletionJul 2010
TodayJul 2026
First PostedJul 30, 2008
Enrollment StartDec 1, 2004
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 17.9 years ago
Interventions
Remicade (Infliximab)biological
Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.